Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials

The American Journal of Medicine

Volumn 75, Issue 1 PART 1, 1983, Pages 40-45

  Mackenzie, Allen H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE;

ADVERSE DRUG REACTION; DRUG DOSE; DRUG THERAPY; EYE TOXICITY; HUMAN; INTOXICATION; JOINT; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; RETINOPATHY; RHEUMATOID ARTHRITIS; THERAPY; VISUAL SYSTEM;

ARTHRITIS, RHEUMATOID; BODY WEIGHT; CHLOROQUINE; COMPARATIVE STUDY; DRUG ADMINISTRATION SCHEDULE; HUMAN; HYDROXYCHLOROQUINE; KIDNEY; LIVER; OPHTHALMOSCOPY; RETINAL DISEASES; SUNLIGHT; TISSUE DISTRIBUTION;

EID: 0020546398     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(83)91269-X     Document Type: Article

References (28)

1. Drugs and ocular tissues
2. Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy
3. Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis or related diseases
4. Long-term maintenance therapy with 4-amino-quinoline compounds in patients with rheumatoid arthritis
5. Chloroquine and hydroxychloroquine in rheumatological therapy
6. An appraisal of chloroquine
7. Let us abandon some cloroquine dogmas [abstr]
8. A decade of chloroquine maintenance therapy: rate of administration governs incidence of retinotoxicity
9. Studies on the chronic toxicity of chloroquine
10. Studies on the chemotherapy of the human malarias VI The physiological disposition antimalarial activity and toxicity of several derivatives of 4-aminoquinoline
11. Laboratory studies of the 4-aminoquinoline antimalarials: II. Plasma levels of chloroquine and hydroxychloroquine in man after various oral dosage regimens
12. Ocular abnormalities in patients treated with synthetic antimalarial drugs
13. Ocular safety of huge cumulative antimalarial dosage [abstr]
14. Ocular damage in chloroquine therapy
15. Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis
16. Incidence of chloroquine retinopathy
17. Retinopathy following the use of chloroquine and allied substances
18. Chloroquine retinopathy Early detection by retinal threshold test
19. Hydroxychloroquine (HCQ) in rheumatoid arthritis (RA) long-term response rate and predictive parameters
20. Chloroquine retinopathy: is there a safe daily dose?
21. Ophthalmologic safety of long-term hydroxychloroquine treatment
22. Ophthalmological examinations of patients taking chloroquine
23. Chloroquine retinopathy in patients with rheumatoid arthritis
24. Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline
25. Influence du niveau d'eclairement ambiant sur les modifications oculaires induites par l'hydroxychloroquine chez le rat
26. Immunophagocytic properties of retinal pigment epithelium cells
27. Light may provide energy for retinal damage during chloroquine therapy
28. The antimalarial drugs for rheumatoid arthritis